Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients


Submitted: 30 January 2021
Accepted: 26 April 2021
Published: 14 March 2022
Abstract Views: 2379
PDF: 470
HTML: 4
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Psoriasis is a chronic condition for which multiple therapies are currently available. In particular, in cases of moderate- severe psoriasis, traditional systemic drugs or the new biological drugs can be administered. However, the treatment of patients who require systemic therapy and have multiple comorbidities can be particularly complex. Some treatment options may be in fact contraindicated or may lose effectiveness over time, reducing the options available to the dermatologists. In such circumstances, dimethyl fumarate may represent a safe and effective choice, also in patients who have already attempted biological therapies. In this regard, we report the case of a patient with moderate-severe psoriasis treated over time with various therapies (including topicals, phototherapy, traditional and biological drugs) that were discontinued due to ineffectiveness or incompatibility caused by the occurrence of concomitant diseases, who finally achieved clinical remission with dimethyl fumarate.


Burlando, M., Molle, M. F., Cozzani, E., & Parodi, A. (2022). Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients. Dermatology Reports, 14(1). https://doi.org/10.4081/dr.2022.9091

Downloads

Download data is not yet available.

Citations

Similar Articles

You may also start an advanced similarity search for this article.